This workshop will feature expert-led discussions, real-world case
demonstrations and collaborative exchanges to optimise your clinical
decision-making in early stage NSCLC management.

Saturday 17 May

13:00–16:45 & Networking dinner from 18:00

13:00–16:45 &
Networking dinner from 18:00
Day 1 AGENDA
Sunday 18 May
08:30–12:45 & Lunch
Day 2 AGENDA
PARKROYAL on Beach Road, Singapore
PARKROYAL
on Beach Road, Singapore
MEET OUR FACULTY

For Healthcare Professionals only.

This is a non-promotional meeting. It is only for registered healthcare professionals (HCPs). This meeting is intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. The content of this meeting may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Please refer to the local prescribing information before using any drugs mentioned in this meeting.

M-XX-00020476
Date of Production: May 2025

Day 1 - Agenda

Saturday 17 May

13:00–16:45 & Networking dinner from 18:00
Event Schedule
Time & Topic
Time
Topic
13:00–13:10
Opening remarks
13:00–13:10
Opening remarks
Session 1: Diagnosis and testing in early-stage NSCLC
13:10–13:20
Opening
13:10–13:20
Opening
13:20–13:50
Overview of diagnosis, testing and patient staging in NSCLC
13:20–13:50
Overview of diagnosis, testing and patient staging in NSCLC
Session 2: MDT for early-stage NSCLC
13:50–13:55
Ideal MDT for early NSCLC: An overview
13:50–13:55
Setting the scene and context: Ideal MDT for early NSCLC
13:55–14:40
Live case demonstration and panel discussion: Optimising the MDT approach in early-stage NSCLC
13:55–14:40
Live case demonstration and panel discussion: Optimising the MDT approach in early-stage NSCLC
14:40–14:55
Tea break
14:40–14:55
Tea break
Session 3: Management of NSCLC patients with driver mutations
14:55–15:00
Opening
14:55–15:00
Opening
15:00–15:20
Oncologists' consideration for management of eNSCLC patients with driver mutation/s
15:00–15:20
Oncologists' consideration for management of eNSCLC patients with driver mutation/s
15:20–15:40
Surgeons’ consideration for management of eNSCLC patients with driver mutation/s
15:20–15:40
Surgeons’ consideration for management of eNSCLC patients with driver mutation/s
15:40–16:10
Case discussion in MDT format: Evaluating treatment approaches for borderline resectable ALK+ and EGFR+ NSCLC
15:40–16:10
Case discussion in MDT format: Evaluating treatment approaches for borderline resectable ALK+ and EGFR+ NSCLC
16:10–16:45
Playback and open discussion
16:10–16:45
Playback and open discussion
18:00
Networking dinner
18:00
Networking dinner

Day 2 - Agenda

Sunday 18 May

08:30–12:45 & Lunch
Event Schedule
Time & Topic
Time
Topic
Session 1: Management of Stage IB and II NSCLC with immunotherapy
08:30–08:35
Opening
08:30–08:35
Opening
08:35–08:55
Surgeons' consideration for management of Stage IB and II patients
08:35–08:55
Surgeons' consideration for management of Stage IB and II patients
08:55–09:15
Oncologists' consideration for management of Stage IB and II patients
08:55–09:15
Oncologists' consideration for management of Stage IB and II patients
09:15–09:45
Case discussion in MDT format: Evaluating treatment approaches for Stage IB and Stage II NSCLC
09:15–09:45
Case discussion in MDT format: Evaluating treatment approaches for Stage IB and Stage II NSCLC
09:45–10:10
Playback and open discussion
09:45–10:10
Playback and open discussion
10:10–10:30
Tea break
10:10–10:30
Tea break
Session 2: Management of Stage III NSCLC with immunotherapy
10:30–10:35
Opening
10:30–10:35
Opening
10:35–10:50
Oncologists' consideration for management of Stage III patients
10:35–10:50
Oncologists' consideration for management of Stage III patients
10:50–11:05
Surgeons' consideration for management of Stage III patients
10:50–11:05
Surgeons' consideration for management of Stage III patients
11:05–11:35
Panel discussion: Is upfront surgery and adjuvant treatment the gold standard for resectable Stage III NSCLC patients?
11:05–11:35
Panel discussion: Is upfront surgery and adjuvant treatment the gold standard for resectable Stage III NSCLC patients?
11:35–12:05
Case discussion in MDT format: Evaluating treatment approaches for PD-L1 low/high, borderline and/or readily resectable NSCLC
11:35–12:05
Case discussion in MDT format: Evaluating treatment approaches for PD-L1 low/high, borderline and/or readily resectable NSCLC
12:05–12:35
Playback and open discussion
12:05–12:35
Playback and open discussion
12:35–12:45
Closing
12:35–12:45
Closing
12:45
Lunch
12:45
Lunch

MEET OUR FACULTY

Steering Committee & Speakers

Professor Chong
Kin Liam

Universiti Malaya
Malaysia

Professor Herbert
Loong

The Chinese University
of Hong kong
Hong Kong

Professor Boon
Hean Ong

National Heart Centre
Singapore

Dr Alan Sihoe

CUHK Medical Centre
Hong Kong

Dr Sing Yang Soon

Sarawak Heart Centre
Malaysia

Dr Aaron Tan

National Cancer
Centre Singapore
Singapore
Speakers

Clin. Asst. Professor
Kevin Lee Min Chua

National Cancer
Centre Singapore
Singapore

Professor Terufumi
Kato

Tokyo Metropolitan
Cancer and Infectious
Diseases Center
Komagome Hospital
Japan

Professor Jii Bum
Lee

Yonsei Medical Center
South Korea

Dr Angela Maria
Takano

Singapore General
Hospital
Singapore